Esperion Therapeutis.Inc. sell nvestor
Summary
This prediction ended on 01.04.23 with a price of €1.43. With a performance of -1.58%, the SELL prediction for Esperion Therapeutis.Inc. by nvestor was down slightly. nvestor has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Esperion Therapeutis.Inc. | -2.991% | -2.991% | 20.000% |
iShares Core DAX® | 2.821% | -1.953% | 15.071% |
iShares Nasdaq 100 | 5.285% | -5.092% | 29.254% |
iShares Nikkei 225® | 3.687% | -4.221% | 14.286% |
iShares S&P 500 | 3.577% | -2.240% | 25.546% |
Comments by nvestor for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.